Results 141 to 150 of about 480,865 (305)
Case Reports in OncologyIntroduction: Mutation in Kristin ras sarcoma virus (KRAS) oncogene is the main driver in pancreatic ductal adenocarcinoma (PDAC) and is present in nearly 90% of patients with PDAC.
Juhi Mody, Mandana Kamgar
doaj +1 more source
Synthetic Toll‐Like Receptors for Control of Innate Immunity With Far‐Red Light
Advanced Science, EarlyView.Synthetic Toll‐like receptors (TLRs) are engineered by replacing their natural sensing regions with a far‐red‐light‐responsive module from a bacterial phytochrome. These synthetic receptors enable light‐controlled regulation of immune signaling in mammalian cells.
Anna V. Leopold, Vladislav V. Verkhusha
wiley +1 more source
, 2010 Background: Mutations of the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients predict the patients who will respond to EGFR tyrosine kinase inhibitor (TKI) treatment.
高劍虹;張逸良;蔡孟峰;吳振都;余忠仁;楊志新;李元麒;楊泮池;施金元 +1 more
core +1 more source
Advanced Science, EarlyView.Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Intracrine Signaling by The Epidermal Growth Factor Receptor
, 2023 The epidermal growth factor receptor (EGFR) is a member of the erbB family of receptor tyrosine kinases. In our study, we were interested to study the intracrine signaling mechanism of the EGF receptor in cells expressing both EGFR and its ligand EGF and
Naceur, Razane
core
Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer
Advanced Science, EarlyView.The mechanisms of SeNPs therapy in cancer treatment, encompass three parallel actions: (1) seleno‐amino acids, key metabolites, upregulate GPX2 expression, thereby inhibiting tumor metastasis via the GPX2‐HIF1α‐VEGF signaling pathway; (2) selenite (SeO32−), an inorganic metabolite, forms hydrogen bonds with amino acid residues 13–17 of the KRAS G13D ...
Xiaoting Liu +13 more
wiley +1 more source
Advanced Science, EarlyView.Aberrant GALNT7‐mediated O‐GalNAcylation stabilizes TAZ to drive gallbladder cancer progression through a feed‐forward transcriptional loop. Structure‐based screening identifies Olaparib as a potent GALNT7 antagonist that disrupts this oncogenic axis, providing an immediate therapeutic strategy for this aggressive malignancy.
Peng Qiu +11 more
wiley +1 more source
Advanced Science, EarlyView.This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu +10 more
wiley +1 more source
EGFR T790M: revealing the secrets of a gatekeeper
, 2017 Brian Ko, Daniel Paucar, Balazs Halmos Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA Abstract: Non-small-cell lung cancers that harbor activating mutations in the EGFR gene represent ...
Halmos B, Ko B, Paucar D
core
Second-Line Treatments after First-Line Gefitinib Therapy in Advanced Nonsmall Cell Lung Cancer
, 2011 Gefitinib is effective as first-line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second-line regimens could lead to better outcomes.
WU, JENN-YU;SHIH, JIN-YUAN;YANG, CHIH-HSIN;CHEN, KUAN-YU;HO, CHAO-CHI;YU, CHONG-JEN;YANG, PAN-CHYR +1 more
core +1 more source